FDA approves darolutamide for treating men with non-metastatic resistant prostate cancer
-
Last Update: 2020-06-02
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
DrMatthew Smith, director of the Urinary Malignancy Malignancy Program at Massachusetts General Hospital Cancer Center, said the approval marks an important new option for prostate cancer groupsprostate cancer, known as desperation-resistant prostate cancer (CRPC), continues to develop even after the level of testosterone in the body is reduced to very low levels" was approved to give doctors more flexibility in treating male patients with nmCRPCRobert LaCaze, executive member of Bayer's Prescription Drug Division and head of the Oncology Strategy Division, said, "Bayer has taken a new step in nmCRPC treatment, the latest in our portfolio of prostate cancerproducts, reflecting Bayer's commitment to finding treatments for male patients with prostate cancer at different stages." "
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.